{"log_id": 338964758583247759, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0, "average": 0.953536, "min": 0.953536}, "location": {"width": 30, "top": 28, "height": 30, "left": 1180}, "words": "监"}, {"probability": {"variance": 0.000763, "average": 0.942332, "min": 0.914712}, "location": {"width": 54, "top": 70, "height": 28, "left": 1169}, "words": "证日"}, {"probability": {"variance": 0, "average": 0.798535, "min": 0.798535}, "location": {"width": 24, "top": 115, "height": 24, "left": 1198}, "words": "到"}, {"probability": {"variance": 1.1e-05, "average": 0.99889, "min": 0.979576}, "location": {"width": 857, "top": 167, "height": 41, "left": 186}, "words": "据,且动物的生殖研究并不能很好预示在人体中的结果。因此,不推荐妊娠妇女使用依"}, {"probability": {"variance": 5e-06, "average": 0.99882, "min": 0.987296}, "location": {"width": 856, "top": 216, "height": 41, "left": 186}, "words": "那西普,建议育龄妇女在依那西普治疗期间不要怀孕。仅在当明确需要时,妊娠妇女才"}, {"probability": {"variance": 0, "average": 0.999503, "min": 0.998124}, "location": {"width": 204, "top": 276, "height": 27, "left": 187}, "words": "可使用依那西普治疗"}, {"probability": {"variance": 3e-06, "average": 0.998526, "min": 0.99496}, "location": {"width": 138, "top": 326, "height": 29, "left": 187}, "words": "哺乳期的使用"}, {"probability": {"variance": 9e-06, "average": 0.998378, "min": 0.985765}, "location": {"width": 813, "top": 366, "height": 40, "left": 230}, "words": "尚未建立哺乳期妇女使用依那西普的安全性,尚不明确依那西普是否通过人的乳汁"}, {"probability": {"variance": 1.1e-05, "average": 0.998528, "min": 0.983406}, "location": {"width": 861, "top": 416, "height": 40, "left": 183}, "words": "分泌。皮下注射给予哺乳期大鼠后,依那西普可以通过乳汁排泄,且可以在胎仔血清中"}, {"probability": {"variance": 3e-06, "average": 0.999067, "min": 0.991413}, "location": {"width": 862, "top": 466, "height": 40, "left": 182}, "words": "检测到依那西普。由于许多药物和免疫球蛋白可由人乳汁分泌,因此哺乳期妇女需考虑"}, {"probability": {"variance": 2e-06, "average": 0.998673, "min": 0.995985}, "location": {"width": 297, "top": 523, "height": 29, "left": 184}, "words": "是否停止哺乳或停用依那西普"}, {"probability": {"variance": 0, "average": 0.999678, "min": 0.999128}, "location": {"width": 94, "top": 623, "height": 27, "left": 191}, "words": "儿童用药"}, {"probability": {"variance": 0, "average": 0.999274, "min": 0.998318}, "location": {"width": 71, "top": 672, "height": 25, "left": 228}, "words": "不适用"}, {"probability": {"variance": 0.000661, "average": 0.979464, "min": 0.927001}, "location": {"width": 105, "top": 770, "height": 28, "left": 186}, "words": "[老年用药]"}, {"probability": {"variance": 2e-06, "average": 0.999184, "min": 0.993707}, "location": {"width": 327, "top": 815, "height": 33, "left": 225}, "words": "无需根据患者年龄进行剂量调整"}, {"probability": {"variance": 0.033342, "average": 0.924133, "min": 0.476873}, "location": {"width": 152, "top": 916, "height": 28, "left": 187}, "words": "药物相互作用1"}, {"probability": {"variance": 5e-06, "average": 0.998167, "min": 0.992114}, "location": {"width": 322, "top": 962, "height": 32, "left": 182}, "words": "依那西普和阿那白滞素联合治疗"}, {"probability": {"variance": 2.1e-05, "average": 0.998389, "min": 0.972244}, "location": {"width": 818, "top": 1005, "height": 38, "left": 228}, "words": "与单独使用依那西普或者阿那白滞素治疗的患者相比,两种药物同时治疗时患者严"}, {"probability": {"variance": 1e-06, "average": 0.999283, "min": 0.995377}, "location": {"width": 341, "top": 1060, "height": 29, "left": 180}, "words": "重感染的发生率更高(历史数据)"}, {"probability": {"variance": 9e-06, "average": 0.998851, "min": 0.981774}, "location": {"width": 824, "top": 1099, "height": 41, "left": 224}, "words": "另外,在一项双盲安慰剂对照的试验中,与单独使用依那西普的患者相比,接受基"}, {"probability": {"variance": 1.8e-05, "average": 0.997663, "min": 0.979503}, "location": {"width": 870, "top": 1148, "height": 40, "left": 178}, "words": "础甲氨蝶呤治疗的患者同时使用依那西普和阿那白滞素后,严重感染(7%)和中性粒"}, {"probability": {"variance": 1.9e-05, "average": 0.998022, "min": 0.979919}, "location": {"width": 870, "top": 1197, "height": 39, "left": 177}, "words": "细胞减少症的发病率增高(参见“注意事项”和“不良反应”)。尚未证实依那西普和阿"}, {"probability": {"variance": 2e-06, "average": 0.999062, "min": 0.995022}, "location": {"width": 593, "top": 1248, "height": 38, "left": 176}, "words": "那白滞素联合用药可以增加临床效果,因此不推荐使用。"}, {"probability": {"variance": 1.4e-05, "average": 0.997873, "min": 0.985634}, "location": {"width": 303, "top": 1303, "height": 30, "left": 176}, "words": "依那西普和阿巴他塞联合治疗"}, {"probability": {"variance": 4.9e-05, "average": 0.998387, "min": 0.95738}, "location": {"width": 828, "top": 1344, "height": 39, "left": 221}, "words": "在临床研究中,依那西普和阿巴他塞联合治疗导致严重不良事件的发生率增加,并"}, {"probability": {"variance": 2e-06, "average": 0.998728, "min": 0.994071}, "location": {"width": 786, "top": 1395, "height": 38, "left": 177}, "words": "未证实这种联合疗法可以增加临床效果,因此不推荐使用(参见“注意事项”)"}, {"probability": {"variance": 2e-06, "average": 0.998728, "min": 0.995171}, "location": {"width": 348, "top": 1450, "height": 29, "left": 177}, "words": "依那西普和柳氮磺胺吡啶联合治疗"}, {"probability": {"variance": 2.7e-05, "average": 0.997758, "min": 0.969659}, "location": {"width": 812, "top": 1492, "height": 39, "left": 220}, "words": "在临床试验中,接受确定剂量柳氮磺胺吡啶治疗的成年患者合并使用依那西普后"}, {"probability": {"variance": 4e-06, "average": 0.998902, "min": 0.988879}, "location": {"width": 872, "top": 1541, "height": 39, "left": 176}, "words": "与单用依那西普和单用磺胺类药物相比,合并用药患者的平均白细胞计数显著下降。尚"}, {"probability": {"variance": 0.001329, "average": 0.987485, "min": 0.866656}, "location": {"width": 282, "top": 1596, "height": 31, "left": 173}, "words": "未明确这一发现的临床意义"}, {"probability": {"variance": 0.000295, "average": 0.989911, "min": 0.93729}, "location": {"width": 156, "top": 1647, "height": 24, "left": 176}, "words": "版本号:20090118"}, {"probability": {"variance": 3.7e-05, "average": 0.995551, "min": 0.983907}, "location": {"width": 177, "top": 1640, "height": 28, "left": 785}, "words": "第14页共31页"}], "language": 3}